Mechanism-Based Pharmacologic Intervention

$124,641P01FY2013CANIH

University Of California, San Diego, La Jolla CA

Investigators

Linked publications, trials & patents

Paper 35230971 Paper 34686499 Paper 34285341 Paper 33714981 Paper 33689703 Paper 33627156 Paper 33615197 Paper 33604581 Paper 33451349 Paper 33081820 Paper 31723042 Paper 31543463 Paper 31292113 Paper 31204237 Paper 31142838 Paper 30967392 Paper 30923040 Paper 30821551 Paper 30712845 Paper 30622177 Paper 30575108 Paper 30568170 Paper 30503705 Paper 30282833 Paper 30242085 Paper 29880603 Paper 29872501 Paper 29859176 Paper 29752258 Paper 29678828 Paper 29263891 Paper 28972595 Paper 28971726 Paper 28923920 Paper 28835371 Paper 28737232 Paper 28526063 Paper 28515090 Paper 28491097 Paper 28465529 Paper 28465528 Paper 28412730 Trial NCT01253460 Trial NCT00265915 Patent 9938350 Patent 9758591 Patent 9480699 Patent 9242014 Patent 9217040 Patent 9051618 Patent 9044474 Patent 9023598 Patent 9017940 Patent 9017939 Patent 9006190 Patent 8911936 Patent 8883749 Patent 8865885 Patent 8658370 Patent 8658362 Patent 8603744 Patent 8580500 Patent 8557520 Patent 8557515 Patent 8530159 Patent 8526583 Patent 8518647 Patent 8512951 Patent 8507202 Patent 8492083 Patent 8486913 Patent 8486912 Patent 8481505 Patent 8431342 Patent 8389210 Patent 8377637 Patent 8361710 Patent 8354229 Patent 8354224 Patent 8349568 Patent 8343725 Patent 8338106 Patent 8338105 Patent 8338104 Patent 8338103 Patent 8338102 Patent 8212009 Patent 8148069 Patent 8084199 Patent 8071315 Patent 8071292 Patent 8034560 Patent 7985584 Patent 7943318 Patent 7723035 Patent 7670840 Patent 7667090 Patent 7601846 Patent 6841565 Patent 6696441

Abstract

PROJECT SUMMARY (See instructions): While development of new therapeutic approaches have contributed to the increase in the complete remission rate for CLL patients, relapses and resistance to re-treatment remain a significant problem. Nevertheless, changes that occur in the biology of CLL upon relapse from front-line therapies provide clues to resistance mechanisms that prevent prolonged complete responses. Our overall strategy is to employ three novel approaches that are each directed at an aspect ofthe pathophysiology of CLL and the mechanisms associated with resistance. First, a deletion at 11q22-23, the site of the ATM gene, occurs in half of relapsed/refractory patients. Mutation ofthe residual allele (-50%) inactivates homologous recombination (HR) repair of double strand breaks. Because Sapacitabine causes one-ended double strand breaks, cells that lack ATM are selectively sensitized. We will develop assays to identify patients who's CLL lacks ATM function, and initiate a clinical trial of Sapacitabine therapy to test the hypothesis that their disease will be selectively sensitized. Second, studies in model systems demonstrate that loss of p53 function is a resistance mechanism to cytotoxic therapy. Nearly half of relapsed refractory patients lack p53 function. We postulate that expression of the epigenetically silenced p73 will serve in place of p53 to activate expression of pro-apoptotic proteins. This will be validated in model systems and tested in a clinical trial. Third, a novel mechanism by which the microenvironment sustains CLL cells and increases resistance to chemotherapy appears to act by providing precursors for glutathione. This sustains CLL by neutralizing the destructive action of reactive oxygen species that are innately over-expressed by CLL. By using a small molecule to reduce glutathione we will test this hypothesis to sensitize CLL cells in vitro and in vivo. These investigations will provide mechanism-based rationales for development of combination therapies.

View original record on NIH RePORTER →